Grants and Contributions:
Title:
Lead discovery to PTSD in-vivo Proof-of-Concept
Agreement Number:
999723
Agreement Value:
$49,790.00
Agreement Date:
Jan 2, 2023 - Mar 31, 2024
Description:
This project is focused on identifying and characterizing highly selective leads for the treatment of a psychological disorder. The latest series of unique compounds will be subjected to thorough in vitro pharmacological investigation to select the best ones for subsequent progression to scale-up and evaluation in a validated animal model.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Montreal, Quebec, CA H4S 1Z9
Reference Number:
172-2022-2023-Q4-999723
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
829528975
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The total amended value is -50,000 dollars.
Amendment Date
Mar 22, 2024
Recipient's Legal Name:
Cyclenium Pharma Inc
Federal Riding Name:
Saint-Laurent
Federal Riding Number:
24068
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
54171
Amendments: